ipilimumab

Patient Alert Card

Information for the patient
Pay attention when using ipilimumab. Ipilimumab is the active substance in the medicine. Your medicine can also have a different (brand) name. Please check carefully which medicine this concerns.

More information
Please read the patient information leaflet for more information about your medicine.

In case of questions about your medicine, please contact your doctor or pharmacist.

This material is approved by the Dutch Medicines Evaluation Board (www.cbg-meb.nl).

Ipilimumab

This card has important information.

Carry your card with you at all times to inform healthcare professionals that you are receiving treatment with ipilimumab.

If you have any signs or symptoms, tell your doctor right away.

BOWEL AND STOMACH

- diarrhoea (watery, loose or soft stools)
- bloody or dark-colored stools
- more frequent bowel movements than usual
- pain or tenderness in your stomach or abdomen area, nausea, vomiting

LIVER

- eye or skin yellowing (jaundice)
- pain on the right side of your stomach area
- dark urine

SKIN

- skin rash with or without itching, dry skin
- blisters and/or peeling of the skin, mouth sores
- swelling of the face or lymph glands

EYE

- redness in the eye
- pain in the eye
- vision problems or blurry vision

NERVES

- muscle weakness
- numbness or tingling in legs, arms or face
- dizziness, loss of consciousness or difficulty waking up

GENERAL

- fever, headache, tiredness
- bleeding
- behavioral changes (e.g. less sex drive, being irritable or forgetful)
- dehydration, low blood pressure

Important information for patients

- Tell your doctor of any previous medical conditions.
- Tell your doctor immediately if you have any signs or symptoms, which do not resolve or become worse.
- Signs and symptoms that may appear mild can quickly worsen if left untreated.
- Do not try to treat these symptoms yourself.
- It is important that side effects are promptly recognised and treated. This reduces the likelihood that your treatment with ipilimumab will need to be temporarily or permanently stopped.
- Signs and symptoms may be delayed and may occur weeks to months after your last ipilimumab injection.

For more information, read the ipilimumab Package Leaflet. You may also call the medical information department at +31 (0)30 3002 222.

Your physician's contact information

Name of your physician

.....

.....

Office phone

.....

.....

After-hours phone

.....

.....

Contact information of the patient

Your name

.....

Your phone number

.....

Contact in case of emergency (ICE):

.....

IMPORTANT information for healthcare providers

- This patient is treated with **ipilimumab** monotherapy.
- Immune-related adverse reactions (irARs) may appear at any time during treatment or months after its discontinuation.
- Early diagnosis and appropriate management are essential to minimise life-threatening complications.
- Consultation with an oncologist or other medical specialist may be helpful for management of organ-specific irARs.
- Healthcare professionals should refer to https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf for the ipilimumab Summary of Product Characteristics (SmPC) or call Medical Information on +31(0)30 3002 222.

The healthcare professional treating this patient with ipilimumab should complete the 'Your physician's contact information' section of this Patient Alert Card.

Contact your doctor if you have an adverse event. Also contact your doctor in case of adverse events which are not described in the patient information leaflet. You can report adverse events via the Netherlands Pharmacovigilance Centre Lareb, website: www.lareb.nl. By reporting adverse events, you help us collect more information about the safety of this medicine.

1506NL2007802 12/20